Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion achieved record-high annual consolidated revenue of KRW 3.56T in 2024 (up 63.45% YoY), driven by expanded global prescriptions of existing products and rapid growth of new products. However, due to higher cost-of-goods-sold from legacy Celltrion Healthcare inventory, amortization of intangible assets (such as sales rights) from the merger, and overseas expansion costs, operating profit declined to KRW 492.0B (down 24.48% YoY).
📊 Key Disclosure Content & Financial Highlights
- Overview
- Company: Celltrion, Inc. (Stock Code: 068270)
- Disclosure Type: Change in Revenue or Profit/Loss Structure Exceeding 15% (Consolidated Basis)
- Large Corporation Status: Applicable
- Board Resolution Date: 2025-02-25
- Consolidated Profit & Loss Changes (Unit: KRW, %)
- Revenue: KRW 3,557,303,554,000 (approx. KRW 3.56T)
- YoY Change: +KRW 1,380,872,023,000 (+63.45%)
- Operating Profit: KRW 492,015,535,000 (approx. KRW 492.0B)
- YoY Change: -KRW 159,465,887,000 (-24.48%)
- Income Before Income Taxes: KRW 576,116,811,000 (approx. KRW 576.1B)
- YoY Change: -KRW 94,978,974,000 (-14.15%)
- Net Income: KRW 418,883,310,000 (approx. KRW 418.9B)
- YoY Change: -KRW 120,823,195,000 (-22.39%)
- Reference Separate Revenue: KRW 3,709,213,743,000 (approx. KRW 3.71T)
- Consolidated Financial Position (Unit: KRW)
- Total Assets: KRW 21,055,222,438,000 (approx. KRW 21.06T)
- Total Liabilities: KRW 3,475,160,069,000 (approx. KRW 3.48T)
- Total Equity: KRW 17,580,062,369,000 (approx. KRW 17.58T)
- Stated Capital: KRW 220,508,291,000
- Total Equity / Capital Ratio: 7,972.52%
- Primary Causes of Changes
- Revenue: Achieved record annual revenue supported by prescription growth of existing products and rapid market adoption of new biosimilars.
- Operating Profit: Impacted by higher COGS from selling higher-cost legacy Celltrion Healthcare inventory, amortization expenses for sales rights arising from the merger, and increased SG&A expenses from expanding global sales subsidiaries.
- Net Income: Decrease resulting directly from the reduced operating profit.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Final Audited Financial Figures and Post-Merger Cost Absorption
This disclosure serves as official notification regarding changes in Celltrion’s financial performance, driven by revenue expansion from product sales alongside merger-related cost factors such as inventory valuation and amortization. Verifying that these provisional figures are finalized without material changes in the audited annual report and checking the progression of merger-related amortization is important for evaluating the stability and accuracy of the financial results. Relevant updates can be confirmed through subsequent audit reports and AGM outcome disclosures.
📢 Disclaimer & Source Notice
Source: This content was structured and generated based on official disclosure data from the Financial Supervisory Service’s DART system.
Investment Risk Warning: This material is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
